Skip to main content
. Author manuscript; available in PMC: 2018 Apr 10.
Published in final edited form as: Eur J Heart Fail. 2016 Oct 17;19(4):552–562. doi: 10.1002/ejhf.674

Figure 3.

Figure 3

Longitudinal NT-proBNP level by atrial fibrillation/flutter (AAF) status (placebo patients only), depicted as univariate (A) and multivariate analysis (B). The y-axis represents the estimated NT-proBNP level in pg/mL, derived from exponentiation of the log-transformed NT-proBNP level at each time point. Multivariate analysis adjusted for age, gender, geographic region, ethnicity, ischaemic heart failure (HF) aetiology, NYHA functional class, medical history (prior HF hospitalization, hypertension, CAD, diabetes, chronic renal insufficiency), background therapies (ACE inhibitor/ARB, beta-blockers, mineralocorticoid receptor antagonist, digoxin, implantable cardioverter-defibrillator, CRT), body mass index, EF, systolic blood pressure, QRS duration, serum creatinine, and the following interactions with study visit: gender, ischaemic HF aetiology, NYHA functional class, beta-blocker, implantable cardioverter-defibrillator. AFFECG, atrial fibrillation/flutter on baseline electrocardiogram.